Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
About
Pricing
Disease Reports
Neurologic gait disorders
MeSH D020233 - neurologic gait disorders
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
See list view
D009461:
Neurologic manifestations
32 Companies
2 Drugs
$
Success rate
D020233:
Neurologic gait disorders
9 Companies
1 Drug
$
Success rate
D020234:
Gait ataxia
0 Companies
0 Drugs
Success rate
D020235:
Gait apraxia
0 Companies
0 Drugs
Success rate
Events Timeline
Commercial
No Data
Clinical Trials
Historical Success Rate
Phase 1
50
%
1/2
Phase 2
33
%
1/3
Phase 3
100
%
2/2
Approved:
2
Overall Success rate:
17%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name
Phase 1
Phase 2
Phase 3
Phase 4
Drug Name
Acorda Therapeutics
Dalfampridine
© 2020-2023 Collaborative Drug Discovery Inc. (CDD) |
Terms of Use